Latest news with #AplasticAnemia
Health Line
27-05-2025
- General
- Health Line
How to Recognize and Treat an Anemia Rash
An anemia rash may be caused by anemia itself or due to complications from anemia treatments. Depending on the type and cause, the rash may look like red or purple pinpoint spots, a bruise, or bumps. There are many different types of anemias with different causes. They all have the same effect on the body: an abnormally low amount of red blood cells. Red blood cells are responsible for carrying oxygen through the body. Some types of anemia can cause rashes, which are abnormalities on the skin. Sometimes, the rash that presents with anemia may be due to the anemia condition itself. Other times, the rash may be due to complications from the treatment of the anemia. Read on to learn more about anemia rashes, including their causes and symptoms, how doctors diagnose them, treatment options, and more. Anemia rash pictures View the slideshow below for photos of anemia rashes. Anemia rash causes and symptoms There are different types of anemia, and the rash may look different with each type. Aplastic anemia Aplastic anemia is a rare condition, and it can be serious. You can develop it or inherit it from a parent. Aplastic anemia occurs when the body's bone marrow doesn't make enough new blood cells. The rashes resemble patches of pinpoint red or purple spots, known as petechiae. These red spots may be raised or flat on the skin. They can appear anywhere on the body but are more common on legs and feet. Petechial spots do not typically cause pain or itching. In aplastic anemia, not only is there a shortage of red blood cells, but there is also a lower-than-normal level of platelets, another type of blood cell. Low platelet count tends to result in bruising or bleeding more easily, leading to bruises that look like rashes. Thrombotic thrombocytopenic purpura Thrombotic thrombocytopenic purpura (TTP) is a rare blood disorder that causes tiny blood clots to form throughout the body. This can cause the tiny red or purple spots known as petechiae, as well as unexplained purplish bruising that can look like a rash. The bruising is known as purpura. Paroxysmal nocturnal hemoglobinuria Paroxysmal nocturnal hemoglobinuria is a rare genetic disorder in which a genetic mutation causes the body to produce abnormal red blood cells that break down too quickly. This can cause blood clots and unexplained bruising. This may look like a rash. Hemolytic uremic syndrome Hemolytic uremic syndrome is a condition in which an immune reaction causes the destruction of red blood cells. The immune reaction can be triggered by bacterial infections, some medications, and even pregnancy. It can cause bruising, which may look like a rash. Iron deficiency anemia Iron deficiency anemia is one of the most common types of anemia. People with iron deficiency may develop pruritus, which is the medical term for itchy skin. As you itch, you may scratch your skin, which can cause a rash-like-appearance. In some cases, treatment for iron deficiency anemia may also cause rashes. Ferrous sulfate is a type of iron supplement that your doctor may prescribe to you if you have iron deficiency anemia. Some people develop an allergy to the ferrous sulfate therapy. This can cause an itchy rash. The rash can appear anywhere on the body and may also cause blistering or peeling. You should seek medical attention immediately if you think you have hives or an allergic rash due to ferrous sulfate, especially if you experience any swelling of the lips, tongue, or throat. Diagnosing anemia rash Your doctor may suspect anemia as the cause of your rash if it meets the physical description and is accompanied by other common anemia symptoms. These include: pale skin fatigue shortness of breath Your doctor may check you for anemia if you display symptoms such as: rapid or irregular heartbeat unexplained bruising prolonged bleeding from cuts, especially minor ones dizziness and headaches nosebleeds bleeding gums frequent infections Tests for anemia include blood tests. If you're experiencing a rash or skin changes, you should make an appointment to see your doctor or dermatologist, especially if: the rash is severe and comes on suddenly with no explanation the rash covers your whole body the rash doesn't improve with home treatment you also experience other symptoms such tiredness, fever, weight loss, or changes in bowel movements If you believe that the rash is a reaction to new iron supplements that you've started taking, seek immediate medical attention. You could be having an allergic reaction or could be taking too high of a dose. Treatments for an anemia rash The best way to treat an anemia rash is to treat the underlying cause. If your doctor diagnoses iron deficiency as a cause, they will likely have you start taking iron supplements. Treating aplastic anemia is sometimes more difficult. Treatments for aplastic anemia can include: blood transfusions immunosuppressant drugs stem cell transplant Other treatments can depend on the specific type of anemia. Your doctor can provide more information about what treatments they recommend. The bottom line Some types of anemia, such as aplastic anemia and thrombotic thrombocytopenic purpura (TTP), can cause petechiae, or pinpoint red or purple spots. They can resemble a rash. Paroxysmal nocturnal hemoglobinuria and hemolytic uremic syndrome can cause bruising, which may also look like a rash. Some people with iron deficiency anemia develop itchy skin. Scratching the skin can cause a rash-like appearance. Some medications for iron deficiency anemia, such as ferrous sulfate, can cause a rash. This allergic reaction is a medical emergency. Contact your doctor if you develop a rash with an unknown cause. Your doctor may order blood tests to confirm anemia or rule out other possible causes. They can then advise on a suitable treatment plan, which typically focuses on addressing the anemia directly.
Cision Canada
22-05-2025
- Business
- Cision Canada
Cellenkos Inc. and King Faisal Specialist Hospital & Research Centre, Sign Strategic MOU to Advance T Regulatory Cell Therapies for Unmet Diseases
KFSHRC to lead Clinical Trials Targeting Aplastic Anemia and Graft vs. Host Disease Cellenkos to Support Local Cell and Gene Therapy Manufacturing at KFSHRC RIYADH, Saudi Arabia and HOUSTON, May 22, 2025 /CNW/ -- King Faisal Specialist Hospital & Research Centre (KFSHRC) and Cellenkos ® Inc., a Texas based clinical stage biotech company, have signed a strategic international memorandum of understanding (MOU) following the Saudi-U.S. Investment Forum 2025, underscoring KFSHRC's commitment to contributing to the advancement of medical innovation and strengthening strategic global collaborations and Cellenkos' resolve to develop T regulatory (Treg) Cell Therapies for treatment of rare diseases with unmet medical needs. This landmark MOU establishes the foundation for strategic collaboration between KFSHRC and Cellenkos to launch the first clinical trial alliance between the Kingdom of Saudi Arabia and the United States. The partnership will begin with two clinical trials evaluating Cellenkos' Treg products for the treatment of Graft vs. Host Disease (GVHD) and Aplastic Anemia. This initiative will pave the way for expanding into neurodegenerative diseases, including Amyotrophic Lateral Sclerosis (ALS) and cardiovascular disorders. Simultaneously, Cellenkos will assist KFSHRC in building local infrastructure for cell and gene therapy manufacturing, training, and education. "At KFSHRC, we remain deeply committed to improving treatment options for patients with Aplastic Anemia and GVHD—conditions that present serious challenges for many individuals and families in our care. We look forward to working together with Cellenkos in a way that serves our patients and supports the advancement of tailored therapeutic solutions," said His Excellency Dr. Majid bin Ibrahim Al Fayyadh, CEO of KFSHRC. "We are thrilled about this partnership and opportunity to work alongside a world-class institution like KFSHRC," said Dr. Simrit Parmar, Founder of Cellenkos and Faculty at Texas A&M University. "Having seen firsthand the sophistication of KFSHRC's bone marrow transplant program—including locally manufactured CD19 CAR T therapies, we're confident that this collaboration will significantly reduce costs and improve patient access. By utilizing KFSHRC's cord blood bank as a local source for manufacturing, we can optimize scalability and impact. This marks the beginning of a transformative era in Treg cell therapy for global healthcare." About KFSHRC KFSHRC is a leading healthcare, research, and education institution recognized throughout Saudi Arabia and the Middle East. Established in 1975, the hospital is committed to providing world-class medical care and continuously advancing healthcare standards within the Kingdom, the Middle East, and the world. KFSHRC's mission is to serve society with the highest level of healthcare and the best patient experience in an integrated education and research setting. KFSHRC performs more than 300 Bone Marrow/Hematopoietic Stem Cell transplants a year, with 250 allogeneic transplants, where 11% of these transplants are for patients afflicted with Aplastic Anemia; 5% afflicted with Congenital BM Failure Syndromes, and another 12% for other bone marrow failure syndromes. KFSHRC has extensive experience in not only treating patients with advanced cell-based therapies such as CAR T, with 58 treatments in 2024 alone, but also has conducted more than 10 CAR T and Gene Therapy clinical trials, has an on-site CAR-T manufacturing facility, and is building a large GMP Cell and Gene Therapy (CAGT) manufacturing facility on site. Additionally, KFSHRC Cord Blood Bank, launched in 2005, has approximately 3,000 stored cord blood units. King Faisal Specialist Hospital & Research Centre has been ranked #1 in the Middle East and North Africa, and #15 globally among the world's top 250 academic medical centers. It is also recognized as the most valuable healthcare brand in the Middle East according to Brand Finance 2024, and named one of the World's Best Smart Hospitals by Newsweek magazine for 2025. About Cellenkos Inc. Cellenkos is a clinical-stage biotechnology company advancing allogeneic, off-the-shelf, cord blood-derived T regulatory (Treg) cell therapies for rare inflammatory and autoimmune diseases. Cellenkos is a clinical-stage biotechnology company based in Houston, Texas, focused on developing off-the-shelf Treg cell therapies for rare inflammatory diseases and autoimmune disorders. Cellenkos' Treg therapies, derived from allogeneic umbilical cord blood and its proprietary CRANE ® platform enables tissue-directed Treg therapies without HLA or ABO matching, suitable for outpatient administration and rapid point-of-care delivery. The company is committed to advancing the development of these promising therapies to improve the lives of patients with rare and underserved conditions. Media Contacts
Yahoo
22-05-2025
- Business
- Yahoo
Cellenkos Inc. and King Faisal Specialist Hospital & Research Centre, Sign Strategic MOU to Advance T Regulatory Cell Therapies for Unmet Diseases
KFSHRC to lead Clinical Trials Targeting Aplastic Anemia and Graft vs. Host Disease Cellenkos to Support Local Cell and Gene Therapy Manufacturing at KFSHRC RIYADH, Saudi Arabia and HOUSTON, May 22, 2025 /CNW/ -- King Faisal Specialist Hospital & Research Centre (KFSHRC) and Cellenkos® Inc., a Texas based clinical stage biotech company, have signed a strategic international memorandum of understanding (MOU) following the Saudi-U.S. Investment Forum 2025, underscoring KFSHRC's commitment to contributing to the advancement of medical innovation and strengthening strategic global collaborations and Cellenkos' resolve to develop T regulatory (Treg) Cell Therapies for treatment of rare diseases with unmet medical needs. This landmark MOU establishes the foundation for strategic collaboration between KFSHRC and Cellenkos to launch the first clinical trial alliance between the Kingdom of Saudi Arabia and the United States. The partnership will begin with two clinical trials evaluating Cellenkos' Treg products for the treatment of Graft vs. Host Disease (GVHD) and Aplastic Anemia. This initiative will pave the way for expanding into neurodegenerative diseases, including Amyotrophic Lateral Sclerosis (ALS) and cardiovascular disorders. Simultaneously, Cellenkos will assist KFSHRC in building local infrastructure for cell and gene therapy manufacturing, training, and education. "At KFSHRC, we remain deeply committed to improving treatment options for patients with Aplastic Anemia and GVHD—conditions that present serious challenges for many individuals and families in our care. We look forward to working together with Cellenkos in a way that serves our patients and supports the advancement of tailored therapeutic solutions," said His Excellency Dr. Majid bin Ibrahim Al Fayyadh, CEO of KFSHRC. "We are thrilled about this partnership and opportunity to work alongside a world-class institution like KFSHRC," said Dr. Simrit Parmar, Founder of Cellenkos and Faculty at Texas A&M University. "Having seen firsthand the sophistication of KFSHRC's bone marrow transplant program—including locally manufactured CD19 CAR T therapies, we're confident that this collaboration will significantly reduce costs and improve patient access. By utilizing KFSHRC's cord blood bank as a local source for manufacturing, we can optimize scalability and impact. This marks the beginning of a transformative era in Treg cell therapy for global healthcare." About KFSHRC KFSHRC is a leading healthcare, research, and education institution recognized throughout Saudi Arabia and the Middle East. Established in 1975, the hospital is committed to providing world-class medical care and continuously advancing healthcare standards within the Kingdom, the Middle East, and the world. KFSHRC's mission is to serve society with the highest level of healthcare and the best patient experience in an integrated education and research setting. KFSHRC performs more than 300 Bone Marrow/Hematopoietic Stem Cell transplants a year, with 250 allogeneic transplants, where 11% of these transplants are for patients afflicted with Aplastic Anemia; 5% afflicted with Congenital BM Failure Syndromes, and another 12% for other bone marrow failure syndromes. KFSHRC has extensive experience in not only treating patients with advanced cell-based therapies such as CAR T, with 58 treatments in 2024 alone, but also has conducted more than 10 CAR T and Gene Therapy clinical trials, has an on-site CAR-T manufacturing facility, and is building a large GMP Cell and Gene Therapy (CAGT) manufacturing facility on site. Additionally, KFSHRC Cord Blood Bank, launched in 2005, has approximately 3,000 stored cord blood units. King Faisal Specialist Hospital & Research Centre has been ranked #1 in the Middle East and North Africa, and #15 globally among the world's top 250 academic medical centers. It is also recognized as the most valuable healthcare brand in the Middle East according to Brand Finance 2024, and named one of the World's Best Smart Hospitals by Newsweek magazine for 2025. Learn more at: About Cellenkos Inc. Cellenkos is a clinical-stage biotechnology company advancing allogeneic, off-the-shelf, cord blood-derived T regulatory (Treg) cell therapies for rare inflammatory and autoimmune diseases. Cellenkos is a clinical-stage biotechnology company based in Houston, Texas, focused on developing off-the-shelf Treg cell therapies for rare inflammatory diseases and autoimmune disorders. Cellenkos' Treg therapies, derived from allogeneic umbilical cord blood and its proprietary CRANE® platform enables tissue-directed Treg therapies without HLA or ABO matching, suitable for outpatient administration and rapid point-of-care delivery. The company is committed to advancing the development of these promising therapies to improve the lives of patients with rare and underserved conditions. Learn more at: Media Contacts KFSHRC: mediacoverage@ Cellenkos: BD@ View original content to download multimedia: SOURCE Cellenkos, Inc. View original content to download multimedia:
